Abbott Laboratories reported a flurry of cardiology and oncology product updates over late October and early November 2026, ...

Abbott Laboratories (NYSE:ABT) reported positive one year VERITAS trial outcomes for its Amulet 360 device in atrial ...

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as fol ...

Abbott Laboratories stock gains as investors weigh the planned Nutrition separation. Abbott expects the transaction to close ...

This company has delivered earnings and dividend growth over time. Abbott’s innovation and a new acquisition could spur more growth in the years to come. 10 stocks we like better than Abbott ...

Abbott Laboratories stock remains in focus as the company advances plans to separate its global Nutrition business into an ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Ken Griffin recently boosted stakes in AbbVie (ABBV +1.41%) and Abbott Laboratories (ABT +1.56%), according to his latest 13F. Griffin is the billionaire founder and CEO of the hedge fund company ...

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Add Yahoo as a preferred source to see more of our stories on Google. Abbott Laboratories, facing hundreds of lawsuits over safety of formula for premature babies, notches a win in federal court A ...

Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income ...

Abbott Laboratories must pay $53 million in compensatory damages in four cases in which Chicago area babies developed a dangerous intestinal disease after consuming the company's formula for premature ...